A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis.

Bennett JL, Grove NC, Johnson RK, Mizenko C, DuPont JC, Wagner BD, Lynch AM, Frohman TC, Shindler KS, Frohman EM

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society1 Jun 2023Cited by 1 (Europe PMC)

PMID37261907PMCIDPMC10414149DOI10.1097/wno.0000000000001878PepBankPUB-37261907

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acute optic neuritis, pRNFL loss at 6 months did not differ between Acthar and IVMP: -13.1 versus -11.7 µm.
In plain wordsIn optic neuritis, retinal nerve layer loss did not differ between Acthar and IVMP at 6 months.
Peptide
ACTH (corticotropin)
Outcome
No significant changepRNFL thickness loss at 6 months
Study
n = 37
Comparator
Intravenous methylprednisolone
Analysis
Primary
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated
Measurements
pRNFL loss
−13.1 µm
Acthar
pRNFL loss
−11.7 µm
IVMP
P
0.88
between groups
Source sentences
Summary
At 6 months, there was no difference in the primary outcome: loss of average pRNFL thickness in the affected eye (RCI vs IVMP: -13.1 vs -11.7 µm, P = 0.88) 6 months after randomization.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190701
02HumanRandomized controlled trialEfficacy outcome
In acute optic neuritis, GC + IPL attenuation did not differ between Acthar and IVMP: -13.8 versus -12.0 µm.
In plain wordsIn optic neuritis, inner retinal layer thinning did not differ between Acthar and IVMP.
Peptide
ACTH (corticotropin)
Outcome
No significant changeGC + IPL thickness attenuation at 6 months
Study
n = 37
Comparator
Intravenous methylprednisolone
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated
Measurements
GC + IPL attenuation
−13.8 µm
Acthar
GC + IPL attenuation
−12 µm
IVMP
P
0.58
between groups
Source sentences
Summary
Additional outcomes also showed no difference between treatment groups: 6-month attenuation of GC + IPL thickness (RCI vs IVMP: -13.8 vs -12.0 µm, P = 0.58) and frequency of pRNFL swelling at 1 month (RCI vs IVMP: 63% vs 72%, P = 0.73) and 3 months (RCI vs IVMP: 26% vs 31%, P = 0.99).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190702
03HumanRandomized controlled trialEfficacy outcome
In acute optic neuritis, pRNFL swelling at 1 month did not differ between Acthar and IVMP: 63% versus 72%.
In plain wordsIn optic neuritis, retinal nerve layer swelling did not differ between Acthar and IVMP at 1 month.
Peptide
ACTH (corticotropin)
Outcome
No significant changepRNFL swelling at 1 month
Study
n = 37
Comparator
Intravenous methylprednisolone
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated
Measurements
pRNFL swelling
63%
Acthar
pRNFL swelling
72%
IVMP
P
0.73
between groups
Source sentences
Summary
Additional outcomes also showed no difference between treatment groups: 6-month attenuation of GC + IPL thickness (RCI vs IVMP: -13.8 vs -12.0 µm, P = 0.58) and frequency of pRNFL swelling at 1 month (RCI vs IVMP: 63% vs 72%, P = 0.73) and 3 months (RCI vs IVMP: 26% vs 31%, P = 0.99).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190703
04HumanRandomized controlled trialEfficacy outcome
In acute optic neuritis, pRNFL swelling at 3 months did not differ between Acthar and IVMP: 26% versus 31%.
In plain wordsIn optic neuritis, retinal nerve layer swelling did not differ between Acthar and IVMP at 3 months.
Peptide
ACTH (corticotropin)
Outcome
No significant changepRNFL swelling at 3 months
Study
n = 37
Comparator
Intravenous methylprednisolone
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated
Measurements
pRNFL swelling
26%
Acthar
pRNFL swelling
31%
IVMP
P
0.99
between groups
Source sentences
Summary
Additional outcomes also showed no difference between treatment groups: 6-month attenuation of GC + IPL thickness (RCI vs IVMP: -13.8 vs -12.0 µm, P = 0.58) and frequency of pRNFL swelling at 1 month (RCI vs IVMP: 63% vs 72%, P = 0.73) and 3 months (RCI vs IVMP: 26% vs 31%, P = 0.99).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190704
05HumanNon-randomized trialEfficacy outcome
In acute optic neuritis, visual function improved with both Acthar and IVMP.
In plain wordsIn optic neuritis, visual function improved with both Acthar and IVMP.
Peptide
ACTH (corticotropin)
Outcome
IncreaseVisual function
Study
n = 19
Comparator
Baseline
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated
Source sentences
Summary
Both treatments resulted in improvement in visual function and PROs.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190705
06HumanNon-randomized trialEfficacy outcome
In acute optic neuritis, patient-reported outcomes improved with both Acthar and IVMP.
In plain wordsIn optic neuritis, patient-reported outcomes improved with both Acthar and IVMP.
Peptide
ACTH (corticotropin)
Outcome
IncreasePatient-reported outcomes
Study
n = 19
Comparator
Baseline
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Both treatments resulted in improvement in visual function and PROs.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals with acute optic neuritis of less than 2 weeks duration were prospectively enrolled and randomized 1:1 to receive either RCI or IVMP.
Report a problemFND-3726190706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 4NCT01838174

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

University of Colorado, Denvern = 37May 2013 to 13 Jan 2022

Multiple Sclerosis

Trial page ClinicalTrials.govUpdated 27 Apr 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.